Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02289820 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate the Safety and Immunogenicity of MEDI7510 in Older Adults

A Phase 1 study of Respiratory Syncytial Virus (RSV), sponsored by MedImmune.

Completed
Registry status
Phase 1
Development phase
363
Enrollment target
5
Study locations

NCT02289820 is a Phase 1 study of Respiratory Syncytial Virus (RSV) that has completed, run by MedImmune. The registered enrollment target is 363 participants, below the 6,723-participant average among 11 other Respiratory Syncytial Virus (RSV) trials with a reported enrollment target (95% lower). The trial reports 5 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02289820, a Phase 1 study of Respiratory Syncytial Virus (RSV), has completed, sponsored by MedImmune.

COMPLETED
Registry status
Phase 1
Development phase
363 participants
Enrollment target
5
Study locations

Study Summary

The goal of this study is to evaluate the safety, tolerability and immunogenicity of ascending doses of adjuvant in combination with a single dosage level of RSV sF in adults 60 years or older who are healthy or who have stable, chronic underlying medical conditions. This study will also provide preliminary safety and immunogenicity data to support concurrent dosing of MEDI7510 with influenza vaccine (IIV), and to assess the safety of MEDI7510 at a dose previously assessed in the Phase 1a study.

Conditions Studied

Respiratory Syncytial Virus (RSV)

Interventions

  • BIOLOGICAL MEDI7510
  • BIOLOGICAL IIV

Study Locations (5)

Florida

  • Research Site - Orlando
  • Research Site - South Miami

Missouri

  • Research Site - Kansas City

North Carolina

  • Research Site - Raleigh

Tennessee

  • Research Site - Nashville

Trial Details

FieldValue
Enrollment Target 363 participants
Start Date 2015-01-05
Est. Completion 2016-02-24
Phase Phase 1

Sponsor

MedImmune

210 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02289820

The ClinicalTrials.gov registry entry for NCT02289820 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 363 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 6,723-participant average among 11 other Respiratory Syncytial Virus (RSV) trials with a reported enrollment target (95% lower). The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Respiratory Syncytial Virus (RSV) appearing as the primary indexed condition, and to 2 interventions - of which MEDI7510 is the first listed.

NCT02289820 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Florida, Missouri, North Carolina.

Frequently Asked Questions

What is clinical trial NCT02289820 about?

NCT02289820 is a clinical study titled "A Study to Evaluate the Safety and Immunogenicity of MEDI7510 in Older Adults". The goal of this study is to evaluate the safety, tolerability and immunogenicity of ascending doses of adjuvant in combination with a single dosage level of RSV sF in adults 60 years or older who are healthy or who have stable, chronic underlying medical conditions. This study will also provide pre...

What is the current status of trial NCT02289820?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 363 participants. The study started on 2015-01-05. Estimated completion is 2016-02-24.

What conditions does trial NCT02289820 study?

This clinical trial studies the following conditions: Respiratory Syncytial Virus (RSV).

What interventions are being tested in trial NCT02289820?

The interventions under investigation include: MEDI7510 (BIOLOGICAL), IIV (BIOLOGICAL).

Who is sponsoring clinical trial NCT02289820?

This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02289820 being conducted?

This trial has 5 study locations across Florida, Missouri, North Carolina, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Respiratory Syncytial Virus (RSV)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Respiratory Syncytial Virus (RSV)

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.